Covance ((CVD)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The clinical study titled An Open-label, Single-dose, Safety and Pharmacokinetic Study of Regadenoson in Pediatric Patients aims to evaluate the safety and pharmacokinetics of Regadenoson, a vasodilator, in pediatric patients. Conducted by GE Healthcare with Covance as a collaborator, this study is significant as it addresses the need for pharmacologic stress perfusion CMR tests in children, adolescents, and infants, potentially improving diagnostic accuracy and patient care in these age groups.
Regadenoson, marketed as Rapiscan®, is the drug being tested in this study. It is administered as a single intravenous bolus dose and serves as a pharmacologic stress agent to aid in myocardial perfusion imaging (MPI), which is crucial for assessing heart function in pediatric patients.
The study follows an interventional, non-randomized, sequential model with no masking, focusing on diagnostic purposes. It involves three cohorts based on age: adolescents, children, and infants. The study design ensures that safety and pharmacokinetic data are reviewed sequentially by a Data Safety Monitoring Board before progressing to younger age groups.
The study commenced on May 20, 2021, with its last update submitted on July 8, 2025. These dates are crucial as they mark the progression and current status of the study, which is still recruiting participants. The primary completion and estimated completion dates are yet to be disclosed.
For investors, this study could have significant market implications. If successful, Regadenoson could become a preferred diagnostic agent in pediatric cardiology, potentially boosting GE Healthcare’s market position and stock performance. Competitors in the pharmaceutical and medical imaging sectors may need to consider this development in their strategic planning.
The study is ongoing, with further details available on the ClinicalTrials portal.